Volume 23, Issue 1 (January 2021) 23, 1–2; 10.4103/aja.aja_35_20

The emerging role of prostate-specific membrane antigen (PSMA) PET-CT in patients with high-risk prostate cancer: moving the bar in high-risk prostate cancer

Jeanny B Aragon-Ching

GU Medical Oncology, Department of Oncology, Inova Schar Cancer Institute, Fairfax, VA, USA

Correspondence: Dr. JB Aragon-Ching (jeanny. aragon-ching@inova.org)

Date of Submission 12-Apr-2020 Date of Acceptance 20-Apr-2020 Date of Web Publication 24-Jul-2020